The company is seeking approval for narsoplimab as a potential treatment for a fatal disease called hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Omeros said it has also requested for a type A meeting with the FDA to resolve any outstanding items.
Price: 5.19, Change: +0.03, Percent Change: +0.58
|Street Color: Global Calendar For Week Ending May 20|
|Ryder System Receives $4.4 Billion Cash Buyout Propo...|
|Payoneer Shares Rally After Q1 Beats Expectations, 2...|
|Market Chatter: Alibaba Group's Venture in Russia Re...|
|Research Alert: CFRA Raises View On Paycom Software ...|